United Therapeutics (UTHR) Total Liabilities (2009 - 2026)

United Therapeutics has disclosed Total Liabilities across 18 years of filings, most recently posting $813.1 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $813.1 million, down 13.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $813.1 million (down 13.2% YoY), and the FY2025 annual result was $783.8 million, down 14.8% from the prior year.
• Total Liabilities came in at $813.1 million for Q1 2026 at United Therapeutics, up from $783.8 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $1.3 billion in Q3 2023 to a low of $734.4 million in Q2 2025.
• The 5-year median for Total Liabilities is $1.2 billion (2024), against an average of $1.1 billion.
• Across the five-year window, Total Liabilities gained 7.55% in 2023 and fell 28.42% in 2025, its largest moves.
• United Therapeutics' Total Liabilities stood at $1.2 billion in 2022, then retreated by 5.26% to $1.2 billion in 2023, then declined by 22.18% to $920.0 million in 2024, then retreated by 14.8% to $783.8 million in 2025, then climbed by 3.74% to $813.1 million in 2026.
• The last three Total Liabilities figures came in at $813.1 million (Q1 2026), $783.8 million (Q4 2025), and $760.9 million (Q3 2025), per Business Quant data.